PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för diflomotecan. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

10 hits

Bibliografisk träff 2015-05-06

Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.

Mangas-Sanjuan V, Mangas-Sanjuan V, Buil-Bruna N, Garrido MJ, Soto E, Trocóniz IF.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.115.223776

Bibliografisk träff 2009-01-01

Diflomotecan, a promising homocamptothecin for cancer therapy.

Kroep JR, Gelderblom H.

Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543780802571674

Bibliografisk träff 2008-07-25

A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.

Graham JS, Falk S, Samuel LM, Cendros JM, Evans TR.

Cancer Chemother Pharmacol · multicenter study; journal article · DOI 10.1007/s00280-008-0795-6

Bibliografisk träff 2007-03-01

A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours.

Scott L, Soepenberg O, Verweij J, de Jonge MJ, Th Planting AS, McGovern D, Principe P, Obach R, Twelves C.

Ann Oncol · multicenter study; clinical trial, phase i; journal article · DOI 10.1093/annonc/mdl439

Bibliografisk träff 2006-09-01

Practical formal total syntheses of the homocamptothecin derivative and anticancer agent diflomotecan via asymmetric acetate aldol additions to pyridine ketone substrates.

Peters R, Althaus M, Diolez C, Rolland A, Manginot E, Veyrat M.

J Org Chem · journal article · DOI 10.1021/jo060928v

Bibliografisk träff 2005-10-28

Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.

Trocòniz IF, Garrido MJ, Segura C, Cendrós JM, Principe P, Peraire C, Obach R.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s00280-005-0112-6

Bibliografisk träff 2004-07-01

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.

Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL.

Clin Pharmacol Ther · research support, u.s. gov't, p.h.s.; journal article · DOI 10.1016/j.clpt.2004.03.003

Bibliografisk träff 2004-03-01

Diflomotecan. Ipsen.

Osheroff N.

IDrugs · review; journal article

Bibliografisk träff 2003-09-01

Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors.

Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Pruñonosa J, Principe P, Twelves C.

Clin Cancer Res · clinical trial; clinical trial, phase i; journal article

Bibliografisk träff 2003-01-01

Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.

Bailly C.

Crit Rev Oncol Hematol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/s1040-8428(02)00090-2